Efficacy should drive atypical antipsychotic treatment
- PMID: 12561827
- PMCID: PMC1125137
- DOI: 10.1136/bmj.326.7383.283/a
Efficacy should drive atypical antipsychotic treatment
Comment on
- 
  
  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.BMJ. 2002 Aug 3;325(7358):243. doi: 10.1136/bmj.325.7358.243. BMJ. 2002. PMID: 12153919 Free PMC article.
References
- 
    - Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry. 2001;58:1172–1176. - PubMed
 
- 
    - Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561–566. - PubMed
 
- 
    - Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002;22:236–233. - PubMed
 
- 
    - Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. J Clin Psychiatry. 2002;63:758–762. - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        